Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 16, 2025ESC Heart FailureOpen Access

Galectin‐3 and kidney function in type 2 diabetes treated with dapagliflozin: Analysis from DECLARE‐TIMI 58

View Full Paper
Ask AI
Bookmark
Share

Authors

PHPaul M. HallerSWStephen D. WiviottDBDavid D. Berg

Discussion

Loading...

Member takes

Overview

Analysis reveals galectin-3 is linked to kidney disease progression in type 2 diabetes, suggesting dapagliflozin may have protective effects.

Key Points

  • Galectin-3 levels were independently associated with kidney disease progression in patients with type 2 diabetes.
  • Among 14,530 participants, a significant risk reduction in kidney disease was observed with dapagliflozin in those with higher galectin-3 levels.
  • The study found significant correlations between baseline galectin-3 and kidney function metrics including eGFR.
  • Dapagliflozin significantly lowered the risk of kidney-related complications, particularly in patients with elevated galectin-3 concentrations.

Cite This Study

Haller et al. (2025) studied this question.

synapsesocial.com/papers/68d42056713b0b5dfea692cahttps://doi.org/10.1002/ehf2.15415
View Full Paper
Ask AI
Bookmark
Share